Evidence verdict: Magnesium is essential for normal physiology, and inadequate status can matter clinically, particularly in older adults and people with gastrointestinal disease, diabetes, alcohol dependence, medication-related losses or impaired intake. Observational studies connect lower magnesium status or intake with frailty, DNA-damage markers and mortality in selected populations.…
Evidence verdict: Omega-3 fatty acids have substantial human evidence for cardiovascular and triglyceride-related outcomes, and higher circulating omega-3 status is often associated with lower mortality in observational cohorts. Human lifespan extension remains unproven for omega-3 supplementation. The 2025 DO-HEALTH analysis found small favorable changes in several DNA-methylation aging…
Evidence verdict: Sulforaphane reliably engages stress-response biology, especially KEAP1-NRF2 signaling, and has been tested in many human trials across disease areas. That makes it more than a purely preclinical molecule, but no trial has shown that sulforaphane extends human lifespan or broadly slows aging. A 2026 older-adult study…
Evidence verdict: Apigenin is scientifically interesting because CD38 is a plausible contributor to age-associated NAD decline and apigenin can inhibit CD38 in experimental models. There is no human evidence that apigenin slows aging or extends lifespan. Human studies mainly describe absorption, metabolism and apigenin-containing foods or extracts in…
Evidence verdict: Current human studies leave quercetin unproven as a stand-alone senolytic or longevity therapy. The strongest human senolytic evidence involving it comes from small studies of dasatinib plus quercetin (D+Q), in which the prescription drug dasatinib is an essential part of the intervention. Quercetin-alone studies of blood…
Evidence verdict: Fisetin has senolytic activity in preclinical models and is being tested in human aging-related trials, but human trials have yet to confirm senolytic effects in people. Published human evidence remains sparse; a tiny, uncontrolled 2024 biological-age pilot was inconsistent, while the AFFIRM trial (NCT03430037) remained active…
Evidence verdict: Berberine can improve some metabolic risk factors in human studies, but there is no clinical evidence that it extends lifespan or has been validated as a human geroprotective therapy. AMPK and other aging-related pathways provide mechanistic plausibility, while heterogeneous trial quality, product variability, gastrointestinal effects and…
Evidence verdict: A properly controlled 120-person ABLE trial is designed to test CaAKG against DNA-methylation age and functional outcomes; recruitment and feasibility reports describe study progress, while efficacy awaits completed, independently interpreted results. The most publicized human “biological age” result came from a small retrospective, multi-ingredient study without…
Evidence verdict: CoQ10 is essential to mitochondrial electron transport and circulating levels can be raised by supplementation, but there is no evidence that CoQ10 extends human lifespan or broadly slows aging. Benefits are better supported in selected cardiovascular settings and some symptom domains than in healthy older adults;…
Evidence verdict: Spermidine is a biologically plausible autophagy-linked geroprotective molecule with strong model-organism evidence and observational human associations. Randomized human evidence remains limited and mixed: the best-known 12-month trial did not improve its primary memory endpoint, so claims that supplementation slows human aging are premature.